![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, March 11, 2024 2:12:08 PM
So 13 of the 13 early OS censors just happened to be in the SOC arm? Wow. What are the odds. Try ..00000014738810721990. Any RA would have a field day with that one.
That didn't happen by chance, because the odds would have been very low as you mention. Let me explain it again in another way.
During all these years, we have seen the following KM charts, number of censors and events:
1. Final PFS numbers for the 232 patients arm from JAMA publication: See chart and notes below.
191 events, 41 censors (232 - 191 = 41), which correspond to about 20% of the patients.
2. Final PFS numbers for the 99 patients arm from JAMA publication: See chart and notes below.
81 events, 18 censors (99 - 81 = 18) , which correspond to about 20% of the patients.
3. Final OS numbers for the 232 patients arm from JAMA publication: See chart and table below.
There were Zero censors for the first two years, as explained in previous post 479394. That is why the survival % directly read from the chart is almost the same amount as the division of: At risk / Initial At Risk. Because of zero censors. See also notes below the table.
4. Interim OS for all 331 patients blended, from JTM publication: See chart below.
There were 13 censored patients (vertical lines in the chart) in the first 19 months and all corresponded to lost to follow up patients, because of the time of enrollment of the last patient in the trial. All these as explained in more detail in my previous post 479394. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168995681
So, as you can see, the only KM analysis that doesn’t have censors is number 3 (Final OS numbers for the 232 patients arm from JAMA publication) and all the others have a very high percentage.
The first natural thought that came to my mind was that if there were 13 censors for the first 19 months in the interim blended (all 331 patients) OS KM chart and none for the final OS KM analysis for the 232 DCVax L arm, and those 13 censors corresponded to lost to follow up, then all of the 13 censors for the first 19 months should correspond to the original 99 patients arm. Just simple logic, as the total 331 patients come from the addition of the two arms mentioned (232 patients arm and 99 patients arm).
So now, because I don´t believe these things happen by chance, I started to think what could be the logical reason for that. And finally came to the conclusion that the majority if not all of these censors should be related to pseudo progressors thought to be real progressors, as I will explain.
In the 99 original placebo arm, every pseudo progressor crossed over because it was thought to be a real progressor is classified immediately not only as a PFS censor, but also as an OS censor. On the other hand, in the 232 DCVax arm, every pseudo progressor thought to be a progressor is only a PFS censor, but not an OS censor.
This also explains what you are saying in the following quote:
So they could detect the psPD in the 99 but not the psPD in the 232. Sure.
The reason is related to the cross over in the trial design. For the case of the 99 patients original placebo arm, the patients didn't receive DCVax at the beginning, but at progression or pseudo progression thought to be progression, they were crossed over and started receiving DCVax.
On the other hand, for the case of the 232 patients DCVax arm, all the progressors or pseudo progressors thought to be progressors have been receiving DCvax from the beginning anyway, so there’s is no reason to censor them for OS analysis.
The 1% difference can explain 13 censors in theory. Censors only effect the step size after them. So if most censors have few events after them they have little effect.
Again, there is not a 1% difference as you are trying to say, it is 0.1% and also 1% would not explain 13 censors. Also censors only effect the step size after them as you say and that precisely reinforces what I am saying, because the sooner the censor occurs, the higher the steps from there, so the survival decrease is higher.
And now you are off the deep end. Anybody with the slightest clue knows that the the original OS of 232 vs 99 would be a huge.
No, that is not true and I gave you my detailed reasons. Now give the reason for what you are saying.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM